Abstract:
본 발명은 패혈증 진단을 위한 정보의 제공방법을 제공함으로써, 환자로부터 분리된 혈액 또는 혈청 또는 혈장으로부터 EphA2 수용체, Ephrin A1의 검출 수준을 측정하여, 신속하게 패혈증 진단을 위한 정보를 제공한다. 또한, 본 발명은 패혈증 환자가 아닌, 정상인으로부터 분리된 생물학적 시료 없이, 패혈증 의심 개체로부터 분리된 생물학적 시료만으로도 패혈증을 결정하여, 패혈증 진단을 위한 정보의 제공방법을 제공한다.
Abstract:
PURPOSE: A pharmaceutical composition for preventing or treating acute lung injury or an acute respiratory failure has excellent effect for preventing or treating acute lung injury or an acute respiratory failure by reducing lung edema and lung damage. CONSTITUTION: A pharmaceutical composition for preventing or treating acute lung injury or an acute respiratory failure includes a soluble RAGE (sRAGE) in a first sequence capable of being coupled to a ligand of a receptor for advanced glycation end products (RAGE), as an active ingredient. The sRAGE obstructs the coupling between the ligand of the RAGE and the RAGE. The RAGE is coupled to the Fc side of an immunoglobulin. The composition suppresses an inflammation. [Reference numerals] (AA) Normal type I & II alveolar epithelium cell; (BB) Neutroph, infiltration of monocyte and erythrocyte cell increase; (CC) Edema of alveolar epithelium cell is observed; (DD) Infiltration in alveolar decreases; (EE) Alveolar epithelium cell doesn't get demaged